Vibe Bio
resources
Case study: Orphan Therapeutics
How Orphan Therapeutics Accelerator Is Optimizing Rare Disease Search & Eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
Webinar: Watch on-demand
The AI buying guide for BD&L executives
The AI buying guide for Business Development & Licensing (BD&L) executives Webinar on-demand Evaluate & choose AI solutions to achieve real results Your biopharma BD&L teams are under unprecedented pressure…
Additional resources
How Orphan Therapeutics Accelerator Is Optimizing Rare Disease Search & Eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
From overwhelm to clarity: prioritizing assets with AI-powered confidence
Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.
From overwhelm to clarity: prioritizing assets with AI-powered confidence
Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches.
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
The Impact Review – Founding Vibe Bio
The Impact Review article explores Alok Tayi’s personal experience with rare disease drove him towards a mission – to fund cures for rare diseases.
STAT – Upending drug industry financing
This article looks at how Vibe Bio CEO, Alok Tayi, is seeking to upend drug industry financing.
Forbes – Alok Tayi’s new start-up is putting drug development into patients’ hands
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.
Endpoint News – Parents become drug developers to save their children’s lives
Endpoint News addressed how parents of children with rare disease are challenging the status quo in drug development.
Coindesk – How Vibe Bio plans to retool biotech funding
In this article, Vibe Bio founder and CEO, Alok Tayi, explains how a decentralized science approach can retool biotech funding.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
Revolutionizing Drug Development for Rare Diseases Through AI | Alok Tayi
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases…
Mother-Son Duo Offer Biopharma KOL Mapping with Adnexi CEO Sandra Shpilberg
Sandra Shpilberg, Co-founder and CEO of Adnexi, discusses using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”
Orphan Therapeutics Accelerator Announces Foundational Partnerships
The Orphan Therapeutics Accelerator, a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.